Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Mar 11;110(7):1688–1697. doi: 10.1038/bjc.2014.120

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2014 Cancer Research UK

This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

PMC Copyright notice

Stratification using NPI+ of those patients in the various classes who received adjuvant chemotherapy for groups (A) luminal (1+2+3), (B) basal (4+5), (C) two basal groups—patients with Basal p53 normal tumours had a good survival overall and no additional stratification could be achieved. (D) HER2 (6+7), (E) HER2+/ER+ and (F) ER+/ER−. There were too few luminal cases receiving chemotherapy to allow development of NPI+ formulae for each of the luminal groups. It can be seen that NPI+ identifies patients with favourable vs poor outcome in all classes assessable apart from the Basal p53 normal class. Time is shown in months.